High-throughput disposable capsules for process-scale anion exchange chromatography.
The "Mustang(R) Q Chromatography Capsule" was developed for the recovery and adsorption removal of biomolecules with a negative charge through anion exchange in bioprocess purification processes. It is suitable for the recovery of biomolecules in the early stages of the purification process, as well as for the removal of negatively charged impurities in subsequent purification steps. With a wide range of sizes available, it can accommodate various processing volumes required in the production of biopharmaceuticals. 【Features】 - Biomolecules with a negative charge easily bind in a single pass. - High flow rates allow for large-scale processing within a single workday. - Ready to use and can be sterilized in an autoclave. - Available in capsule or cartridge format. - Compared to traditional columns that require packing and cleaning validation, it reduces operational costs and capital investment. *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 ■ Manufactured in accordance with the high quality assurance standards of BS EN ISO9002;1997 ■ Membranes are tested for dynamic binding capacity and peak position using standard proteins for each lot ■ Identified by lot number and unique serial number for complete traceability of manufacturing history that meets strict QC/QA requirements ■ Accompanied by a certificate of inspection that demonstrates the quality and quality control of Pole Corporation ■ Extensive validation is conducted to ensure consistently reliable performance *For more details, please refer to the PDF materials or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
